EP Patent

EP4288041A1 — Amiselimod for preventing, treating, or ameliorating ulcerative colitis

Assigned to Bausch Health Ireland Ltd · Expires 2023-12-13 · 2y expired

What this patent protects

Described herein are methods for treating ulcerative colitis (UC) as well as other inflammatory gastrointestinal disorders using amiselimod. The method of treatment includes dosing amiselimod at a larger initial dose as compared to the eventual maintenance dose.

USPTO Abstract

Described herein are methods for treating ulcerative colitis (UC) as well as other inflammatory gastrointestinal disorders using amiselimod. The method of treatment includes dosing amiselimod at a larger initial dose as compared to the eventual maintenance dose.

Drugs covered by this patent

Patent Metadata

Patent number
EP4288041A1
Jurisdiction
EP
Classification
—
Expires
2023-12-13
Drug substance claim
No
Drug product claim
No
Assignee
Bausch Health Ireland Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.